Cargando…

Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1

Cyclic AMP promotes EPAC1 and EPAC2 activation through direct binding to a specific cyclic nucleotide-binding domain (CNBD) within each protein, leading to activation of Rap GTPases, which control multiple cell responses, including cell proliferation, adhesion, morphology, exocytosis, and gene expre...

Descripción completa

Detalles Bibliográficos
Autores principales: M. Beck, Elizabeth, Parnell, Euan, Cowley, Angela, Porter, Alison, Gillespie, Jonathan, Robinson, John, Robinson, Lindsay, Pannifer, Andrew D., Hamon, Veronique, Jones, Philip, Morrison, Angus, McElroy, Stuart, Timmerman, Martin, Rutjes, Helma, Mahajan, Pravin, Wiejak, Jolanta, Luchowska-Stańska, Urszula, Morgan, David, Barker, Graeme, Rehmann, Holger, Yarwood, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912754/
https://www.ncbi.nlm.nih.gov/pubmed/31726720
http://dx.doi.org/10.3390/cells8111425
_version_ 1783479531647008768
author M. Beck, Elizabeth
Parnell, Euan
Cowley, Angela
Porter, Alison
Gillespie, Jonathan
Robinson, John
Robinson, Lindsay
Pannifer, Andrew D.
Hamon, Veronique
Jones, Philip
Morrison, Angus
McElroy, Stuart
Timmerman, Martin
Rutjes, Helma
Mahajan, Pravin
Wiejak, Jolanta
Luchowska-Stańska, Urszula
Morgan, David
Barker, Graeme
Rehmann, Holger
Yarwood, Stephen J.
author_facet M. Beck, Elizabeth
Parnell, Euan
Cowley, Angela
Porter, Alison
Gillespie, Jonathan
Robinson, John
Robinson, Lindsay
Pannifer, Andrew D.
Hamon, Veronique
Jones, Philip
Morrison, Angus
McElroy, Stuart
Timmerman, Martin
Rutjes, Helma
Mahajan, Pravin
Wiejak, Jolanta
Luchowska-Stańska, Urszula
Morgan, David
Barker, Graeme
Rehmann, Holger
Yarwood, Stephen J.
author_sort M. Beck, Elizabeth
collection PubMed
description Cyclic AMP promotes EPAC1 and EPAC2 activation through direct binding to a specific cyclic nucleotide-binding domain (CNBD) within each protein, leading to activation of Rap GTPases, which control multiple cell responses, including cell proliferation, adhesion, morphology, exocytosis, and gene expression. As a result, it has become apparent that directed activation of EPAC1 and EPAC2 with synthetic agonists may also be useful for the future treatment of diabetes and cardiovascular diseases. To identify new EPAC agonists we have developed a fluorescent-based, ultra-high-throughput screening (uHTS) assay that measures the displacement of binding of the fluorescent cAMP analogue, 8-NBD-cAMP to the EPAC1 CNBD. Triage of the output of an approximately 350,000 compound screens using this assay identified a benzofuran oxaloacetic acid EPAC1 binder (SY000) that displayed moderate potency using orthogonal assays (competition binding and microscale thermophoresis). We next generated a limited library of 91 analogues of SY000 and identified SY009, with modifications to the benzofuran ring associated with a 10-fold increase in potency towards EPAC1 over SY000 in binding assays. In vitro EPAC1 activity assays confirmed the agonist potential of these molecules in comparison with the known EPAC1 non-cyclic nucleotide (NCN) partial agonist, I942. Rap1 GTPase activation assays further demonstrated that SY009 selectively activates EPAC1 over EPAC2 in cells. SY009 therefore represents a novel class of NCN EPAC1 activators that selectively activate EPAC1 in cellulae.
format Online
Article
Text
id pubmed-6912754
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69127542020-01-02 Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1 M. Beck, Elizabeth Parnell, Euan Cowley, Angela Porter, Alison Gillespie, Jonathan Robinson, John Robinson, Lindsay Pannifer, Andrew D. Hamon, Veronique Jones, Philip Morrison, Angus McElroy, Stuart Timmerman, Martin Rutjes, Helma Mahajan, Pravin Wiejak, Jolanta Luchowska-Stańska, Urszula Morgan, David Barker, Graeme Rehmann, Holger Yarwood, Stephen J. Cells Article Cyclic AMP promotes EPAC1 and EPAC2 activation through direct binding to a specific cyclic nucleotide-binding domain (CNBD) within each protein, leading to activation of Rap GTPases, which control multiple cell responses, including cell proliferation, adhesion, morphology, exocytosis, and gene expression. As a result, it has become apparent that directed activation of EPAC1 and EPAC2 with synthetic agonists may also be useful for the future treatment of diabetes and cardiovascular diseases. To identify new EPAC agonists we have developed a fluorescent-based, ultra-high-throughput screening (uHTS) assay that measures the displacement of binding of the fluorescent cAMP analogue, 8-NBD-cAMP to the EPAC1 CNBD. Triage of the output of an approximately 350,000 compound screens using this assay identified a benzofuran oxaloacetic acid EPAC1 binder (SY000) that displayed moderate potency using orthogonal assays (competition binding and microscale thermophoresis). We next generated a limited library of 91 analogues of SY000 and identified SY009, with modifications to the benzofuran ring associated with a 10-fold increase in potency towards EPAC1 over SY000 in binding assays. In vitro EPAC1 activity assays confirmed the agonist potential of these molecules in comparison with the known EPAC1 non-cyclic nucleotide (NCN) partial agonist, I942. Rap1 GTPase activation assays further demonstrated that SY009 selectively activates EPAC1 over EPAC2 in cells. SY009 therefore represents a novel class of NCN EPAC1 activators that selectively activate EPAC1 in cellulae. MDPI 2019-11-12 /pmc/articles/PMC6912754/ /pubmed/31726720 http://dx.doi.org/10.3390/cells8111425 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
M. Beck, Elizabeth
Parnell, Euan
Cowley, Angela
Porter, Alison
Gillespie, Jonathan
Robinson, John
Robinson, Lindsay
Pannifer, Andrew D.
Hamon, Veronique
Jones, Philip
Morrison, Angus
McElroy, Stuart
Timmerman, Martin
Rutjes, Helma
Mahajan, Pravin
Wiejak, Jolanta
Luchowska-Stańska, Urszula
Morgan, David
Barker, Graeme
Rehmann, Holger
Yarwood, Stephen J.
Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1
title Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1
title_full Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1
title_fullStr Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1
title_full_unstemmed Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1
title_short Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1
title_sort identification of a novel class of benzofuran oxoacetic acid-derived ligands that selectively activate cellular epac1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912754/
https://www.ncbi.nlm.nih.gov/pubmed/31726720
http://dx.doi.org/10.3390/cells8111425
work_keys_str_mv AT mbeckelizabeth identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT parnelleuan identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT cowleyangela identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT porteralison identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT gillespiejonathan identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT robinsonjohn identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT robinsonlindsay identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT panniferandrewd identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT hamonveronique identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT jonesphilip identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT morrisonangus identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT mcelroystuart identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT timmermanmartin identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT rutjeshelma identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT mahajanpravin identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT wiejakjolanta identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT luchowskastanskaurszula identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT morgandavid identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT barkergraeme identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT rehmannholger identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1
AT yarwoodstephenj identificationofanovelclassofbenzofuranoxoaceticacidderivedligandsthatselectivelyactivatecellularepac1